摘要
Abstract
Objective:To investigate the clinical value of metformin combined pioglitazone in treatment of refractory type 2 diabetes .Methods :204 cases of refractory type 2 diabetes in our hospital from January 2011to De-cember 2012 were collected and randomly divided into two groups ,each 102 cases .Patients in control group were treated with metformin ,and patients in observation group were treated with metformin combined pioglitazone .After treatment 6 months ,the efficacy ,adverse reactions ,and changes of fasting blood glucose (FBG ) ,2h postprandial blood glucose (PBG) and glycosylated hemoglobin (HbA1C) of two groups were compared .Results :After treat-ment 6 months ,the effective rate of observation group was 93 .1% (95/102) ,which was significantly higher than that in control group 76 .4% (55/72) ,P<0 .05 .After treatment ,the FBG ,2h PBG and HbA1C level of two groups significantly improved ,and the FBG ,2h PBG and HbA1C level of observation group were significantly lower than that in control group ,P<0 .05 .There were some slightly adverse reactions in two groups ,but the difference was no significant ,P>0 .05 .Conclusion:Metformin combined pioglitazone can significantly improve blood sugar and gly-cosylated hemoglobin levels in type 2 diabetes ,the efficacy is good ,and should be promoted .关键词
糖尿病,非胰岛素依赖型/药物疗法/二甲双胍/吡格列酮Key words
Diabetes mellitus ,non-insulin-dependent/drug therapy/Metformin/Pioglitazone分类
医药卫生
